Analyst Rating Update on Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals (INO) : 5 brokerage houses believe that Inovio Pharmaceuticals (INO) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

Inovio Pharmaceuticals (INO) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $31 and the lowest price target forecast is $13. The average forecast of all the analysts is $18.6 and the expected standard deviation is $7.23.

For the current week, the company shares have a recommendation consensus of Buy.


Inovio Pharmaceuticals (NASDAQ:INO): The stock opened at $9.61 on Wednesday but the bulls could not build on the opening and the stock topped out at $9.74 for the day. The stock traded down to $9.15 during the day, due to lack of any buying support eventually closed down at $9.60 with a loss of -5.51% for the day. The stock had closed at $10.16 on the previous day. The total traded volume was 3,051,581 shares.

Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.